Identification of needs in biomarker research. by Ward, J B & Henderson, R E
Identification of Needs in Biomarker Research
Jonathan B. Ward Jr.1 and Rogene E. Henderson2
1Department of Preventive Medicine and Community Health, University
ofTexas Medical Branch, Galveston, Texas; 21nhalation Toxicology
Research Institute, Albuquerque, New Mexico
Interest in the use of biological markers to evaluate future disease risk has increased greatly in
recent years. Biomarkers are observable end points in a continuum of events leading from expo-
sure to toxic agents to diseases that ultimately result from exposure. Because many significant
diseases develop over long periods of time, methods for detecting early events that can predict
risk are important for disease prevention. Biomarkers are generally categorized as detecting expo-
sure, effects of exposure, or individual susceptibility to exposure. Although there has been
significant progress in the technical development of biomarkers, implementation of their use in
human populations has progressed much more slowly. We discuss four major needs in the
development of biomarkers. First, new biomarkers need to be developed to fill gaps in our ability
to observe steps in the continuum from exposure to disease. Second, the relationships between
biomarker responses and disease pathology needs to be better understood. Third, the sensitivity,
specificity, and variability of biomarkers need to be better characterized and they must be better
validated as predictors of disease risk. Fourth, there are several societal impediments to the prac-
tical implementation of biomarker studies as public health tools. A common agreement among
employers, employees, regulators, and the legal community must be established regarding
appropriate and ethical uses and interpretation of biomarker data. Environ Health Perspect
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Introduction
The use of biological markers in the
evaluation of disease risk has increased
markedly in the last decade. Biomarkers
are observable end points that indicate
events in the processes leading to disease.
They are particularly useful in the evalua-
tion of progressive diseases that manifest
their symptoms long after exposure to ini-
tiating factors. In such cases, traditional
early warning symptoms ofdeveloping dis-
ease may be lacking. At the same time, the
disease, once clinically apparent, may
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be essentially irreversible. Diseases such
as cancer and neurological disorders
are examples.
The Committee on Biological Markers
of the National Research Council (1)
developed a conceptual framework for bio-
logical markers (Figure 1) describing a con-
tinuum of events from exposure to the
development ofdisease. For a slowly devel-
oping disease, the events through early bio-
logical effects can be detected at about the
time of exposure. Because the later stages
ofthe process, in which the clinical symp-
toms of disease emerge, may not appear
for years, detection of earlier events can
provide a valuable early warning of risk.
Interventions to reduce the long-term risk,
such as control of exposure, may then be
made possible.
Biomarkers are generally classified into
three groups; biomarkers of exposure,
effect, or susceptibility (1). A typical bio-
marker ofexposure would be the level ofa
toxic substance, such as lead, in the blood
or urine of an individual. An effect bio-
marker is the biological response to an
exposure. Somatic cell mutation in
response to a mutagen exposure (2), or
reduced cholinesterase activity in response
to an organophosphate insecticide exposure
are examples (3). Biomarkers of suscepti-
bility measure innate or induced capa-
bilities of the individual for response to
exposure to an environmental toxicant.
These might include the activity ofspecific
enzymes involved in activation or detoxifi-
cation of a specific chemical (4) or DNA
repair capacity for specific types of DNA
damage (5). Some biomarkers fall at the
boundaries between these classifications.
For example, a DNA adduct may be asso-
ciated with a specific chemical, making it
characteristic of a biomarker of exposure,
but its formation may result from the
metabolism, distribution, and reaction of
the chemical with DNA, which reflects cel-
lular processes. Thus, to a degree, it is an
effect biomarker as well. Typically, expo-
sure biomarkers are specific to the chemical
producing the exposure, while effect bio-
markers may be responses to any ofa class
of chemicals. Studies of populations with
exposures to mixtures ofchemicals should
use combinations of exposure and effect
biomarkers. An exposure biomarker alone
may document exposure but give little
information about its biological signifi-
cance, while an effect biomarker alone may
reveal an increased incidence ofan adverse
effect without documenting a cause.
In addition to providing an early
warning ofpotential future adverse effects
ofexposure, biomarkers mayprovide useful
information about the mechanisms oftoxi-
city in human subjects. Since most bio-
markers that can be used in human studies
can also be observed in laboratory animals,
experimental studies in animals can be
used to study the mechanisms leading to
the expression of biomarkers in ways that
are not appropriate in most human studies.
Although the last decade has seen rapid
advances in the development of methods
for biological monitoring, there has been
less progress in their application to the
assessment of human exposures, particu-
larly in the United States. Reasons for this
include limited federal funding for research
in this area, lack of access to populations
for study, and unresolved concerns about
legal and ethical issues that might develop
from human population studies.
Here we identify four major needs for
the continued development and applica-
tions ofbiological markers to environmen-
tal health research. First, new biomarkers
need to be developed, or existing ones
refined to fill gaps in the continuum of
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Figure 1. Biological markers and disease progression. A toxicantentering the bodyproduces an
consequence of its disposition and metabolism. Interactions of the agent or its metabolites wit
molecules determine the biologically effective dose at a target tissue, which may result in
These may result in altered structure or function, which eventually leads to clinical disease. Ev
row occur within a short time after exposure and may serve as useful b'omarkers. Events alor
may occur later and are usually not observable much before the occurrence of clinical disease. E
biomarkers are shown for specific events. Factors affecting individual susceptibility may impac
shown. From the National Research Council(1).
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effect parallelogram approach. Research to
develop biomarkers that are more relevant
to specific diseases, and are observed in
relevant target tissues, is amajor need.
Existing techniques need to be refined
and new ones developed to improve the b.. Altered accuracy, sensitivity, and efficiency ofbio- structure markers. The volume ofbiological materi- function
als required by many current techniques
limits their usefulness and restricts the
Inactive numbers of tests that can be performed in
suppressor combination on samples from a single gene specimen. Refinement of techniques to
internal dose as a allow useful results to be obtained from a
th cells and macro- smaller sample would be helpful. In some
biological effects. cases, this might open additional tissues to
ients along the top observation by reducing the numbers of
ng the bottom row cells needed. Current tests are often com- Examples oftypical plex and expensive to run. Changes that ct any of the steps simplify and/or automate the more time-
consuming aspects of these techniques
would also be useful.
'eused as early Application of Biomarkers risk of cancer.
to Risk Assessment irly a relevant
.ither of these Because biomarkers represent steps on the
dly involved in exposure-disease continuum, they have
n addition, the potential applications in risk assessment.
in peripheral Biomarkers can facilitate the linking of
:ells may have exposure to given amounts of a chemical
)oietic cancers, with the induction of specific health
Dr some of the effects. Figure 2 illustrates some of the
y, mutations at types ofbiomarkers that can help trace the
cally related to steps from the initial exposure to the
or genes, would induction of an adverse health effect.
)n, it would be All ofthe chemical to which a person is
r cell types that exposed will not be absorbed; what is
ies of interest absorbed is the defined as the internal dose.
irectly or indi- Some ofthis dose may be excreted without
.iallenges, since resulting in health effects, some may end
ig or screening up in tissues that are not affected by the
currently exist. chemical, but some may reach a target tis-
s are not easily sue that is vulnerable to the chemical or its
bjects in large metabolites. Ofthe dosereaching the target
otably invasive tissue, some may not reach critical organ-
es. A potential elles, some may form noneffective macro-
rould be to use molecular adducts, but some amount, the
h described by biologically effective dose, may reach a site
Lan biomarkers that will result inbiological alterations that
parts could be may lead to disease.
ratio ofeffects The most useful markers of effect
cal effect in the (Figure 2) are the earliest events on the
le experimental pathway to the development of a disease
.d and used to state. Such markers may allow intervention
iman target tis- in the disease process before it becomes
humans and irreversible. As in the markers ofexposure,
he disposition some of the early biological changes may
locus in erythrocytes (7) an
biological effect markers for
Although mutation is clea
event preceding cancer, ne
genetic loci are mechanistica
the carcinogenesis process. h
measurements are made
blood cells. While these c
some relevance for hematop
they may not be relevant fc
other types of tumors. Ideall,
genetic loci that are specifi(
neoplasia, such as suppresso.
be more relevant. In additio
helpful if events inparticulai
are relevant to malignanci
could be evaluated either di
rectly. These are difficult ch
no direct means for selectin
for rare mutants at such loci
In addition, relevant tissues
obtained from human sul
numbers without unaccep
techniques, such as biopsit
approach to this problem w
the parallelogram approact
Sobels (8). Accessible hum
and their animal counter[
compared to determine the
in the twospecies. Abiologi(
target tissue ofinterest in th
animal would be measurei
estimate the effect in the hu
sue. Differences between
experimental animals in t]
events from exposure to clinical disease
expression. Second, the relationships of
specific biomarkers to thepathophysiologi-
cal mechanisms of disease must be better
understood to moreaccurately estimate the
risk ofdisease from evidence based on bio-
markers. Third, biomarkers need to be bet-
ter characterized with respect to their
sensitivity, specificity, and variability, as
well as validated as predictors of adverse
health effects. Fourth, many issues related
to the application ofbiomarker research to
real-world situations need to be resolved.
Method Improvements
Biomarkers reflect discrete steps in the
continuum of events leading from toxic
chemical exposure to disease. To better
understand the relevance ofthese events to
disease risk, it would be desirable to define
the continuum at a level of resolution as
high as possible. There is a need for expo-
sure biomarkers that identify a greater vari-
ety ofchemicals and their metabolites. At
this time such biomarkers exist for only a
small number of chemicals. Better assess-
ment ofhuman exposures to toxicants will
require measures of exposure to a greater
variety ofchemicals.
Biomarkers of effect are frequently
surrogate measures for events on the expo-
sure-disease continuum but are not on the
continuum themselves. Forexample, soma-
tic mutation biomarkers at the HPRTIocus
in lymphocytes (6) or the glycophorin A
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Figure 2. Application of biomarkers to risk assessment. The diagram represents the many paths a chemical may
take after entering the body, leading to alternative fates including detoxification or injury and disease. The left box
represents disposition of the chemical, the center box its metabolism and effects on target tissues, and the right
box observable responses, some of which lead to clinical disease. Biomarkers of exposure predominantly detect
events in the left box, while biomarkers of effect detect events in the center and right boxes. From Henderson (20),
with permission.
not lead to disease, but instead are repaired.
Some of the early changes induced by the
chemical or its metabolites may not be on
the pathway to disease, but are only physi-
ological responses that are protective to the
organism. Eventually, if there are enough
changes that can result in disease and ifthe
changes persist long enough without
repair, a disease state may ensue.
Ideally, if one understood the quantita-
tive, kinetic relationships between each of
the markers shown in Figure 2, one could
use the markers both to determine the
degree ofprior exposure and to predict the
potential for adverse health effects from the
exposure. Even markers that are not on the
pathway leading to disease (such as hemo-
globin adducts) can be useful ifthe quanti-
tative relationship between these markers
and the markers that are on the pathway is
known. It is necessary to move past the
stage ofnoting that markers such as hemo-
globin and DNA adducts exist to deter-
mining the quantitative relationship
between the amount ofthe adducts and the
previous exposures as well as the probabil-
ity of disease development. An example of
the difference between a qualitative and a
quantitative approach to biomarkers can be
seen in the detection of ethanol on the
breath of someone who has been drinking
alcoholic beverages. If one is the parent of
a teenager, one need only detect the smell
of ethanol on the child's breath to take
whatever action is required. If one is in the
regulatory arena, however (i.e., a law
enforcement officer) one must quantitate
how much ethanol is in the person's breath
and how that amount relates to inebriation
before taking action.
The markers of exposure illustrated on
the left side of Figure 2 are quantities that
have long been studied in pharmacokinet-
ics. Measures of the rate of formation of
such markers following a given exposure
and the rate at which they are cleared have
led to the development of mathematical
models that predict the level ofthe markers
under different exposure situations. Figure
3 illustrates one approach to developing
mathematical models for the disposition of
chemicals in humans. First, the kinetic
parameters are studied in animals and
mathematical models are developed based
on this kinetic information, plus physio-
logical parameters such as blood flow rates,
breathing rates, and other information as
needed. Other important components of
the model are the physicochemical proper-
ties ofthe chemical and its metabolites and
how the agents partition between air and
blood and between blood and tissues.
When the animal model is complete, then
Detailed
toxicokinetic
studies in
animals
Percent absorbed
Tf/2 to steady state
Major routes and rates
of excretion
TI/2 for clearance
the model can be modified based on
human physiological parameters. Such
models must then be validated with what-
ever data are available from humans acci-
dentally or occupationally exposed to the
chemical. Through such approaches,
progress has been made in quantitating and
modeling biomarkers ofexposure.
The use of the biomarkers that are
illustrated on the right side ofthe Figure 2
has been the purview of clinical medicine
for centuries. Similar approaches to those
used in the pharmacokinetic area could be
used to determine the kinetics of disease
processes to provide pharmacodynamic
models ofdisease development. This type
ofresearch is only in its infancy and should
be an area for future emphasis.
Perhaps the greatest need is for more
mechanistic research on the early stages of
disease development, as depicted in the
center of Figure 2. One cannot have a
marker ofthe biologically effective dose for
a chemically induced disease if one does
not know the mechanism ofthe induction.
One cannot detect preclinical signs ofdis-
ease development without knowledge of
the early steps in that disease process. Thus,
mechanistic research will undoubtedly be a
major source of future biomarkers of the
earliest stages ofchemically induced adverse
health effects.
At the current time, we often have
more biomarkers than we can adequately
interpret. For example, ifwe find chemical-
specific DNA adducts in a person today we
have no way of predicting what those
adducts mean in terms ofthe probability of
an impact on the future health ofthat indi-
vidual. It is essential that we begin to fill in
the blanks in the steps between exposure to
chemicals and disease development so that
biomarkers can become more useful in the
risk assessment process.
Mathematical
model of Mathematical Validate
disposition in ' model '. human
animals for humans model
Animal toxicokinetic data
Animal physiological data
Human physiological data Limited human data
Effect of concentration,
rate, route, repeated
exposure
Figure 3. Use of animal toxicokinetic data in human risk assessment. This diagram depicts a scheme by which
animal toxicokinetic data may be used in the development and interpretation of a human biomarker. The lower
rows depict the types of data that may be generated at each step in the process. From Henderson et al. (21), with
permission.
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Characterization and
Validation of Biomarkers
To be ofpractical utility in the evaluation
of human population exposures to toxic
agents, certain basic parameters of a bio-
marker must be known, and thevalue ofthe
biomarker as a predictor ofdisease should
be understood. In other words, to be useful
a biomarker must be characterized and, to
the extent possible, it must be validated.
The primary characteristics of concern
for a biomarker are similar to those that are
determined for most clinical laboratory
procedures. Some adjustments must be
made, however, to accommodate the fact
that biomarkers are typically used to evalu-
ate populations rather than individuals.
Most biomarkers have a baseline response
that is observed even in populations with
no specific exposure to a toxic substance.
Thus, DNA adducts are observed at some
concentration in tissues from nonexposed
subjects (9). The frequency ofmutations at
the HPRTlocus in human lymphocytes
has a baseline of one to two per million
cells in the autoradiographic version ofthe
assay (10) and a somewhat higher value in
the clonal version ofthe assay (11). These
"spontaneous" responses for biomarkers
may result from the endogenous formation
of chemicals detected by exposure bio-
markers or the spontaneous occurrence of
process such as mutation, which are
detected as effect biomarkers. Alternatively,
ambient exposure to low levels ofchemicals
that elicit biomarker responses may be
responsible. In any case, the historical base-
line response of a biomarker in a popula-
tion with no unusual exposure to the toxic
agent of interest should be known, and
studies ofpopulations potentially exposed to
toxic agents should include an appropriate
control or referent group.
As with clinical tests, the sensitivity and
specificity of a biomarker assay are charac-
teristics that must be known to determine
appropriate circumstances for its use.
Sensitivity is a fairly straightforward para-
meter to determine. Laboratory experi-
ments with spiked samples and animal
studies can be used to determine the ana-
lytical limits of detection of a biomarker.
Finally, it is possible to obtain a reasonable
estimate ofthe exposures of individuals or
populations to the agent of interest by an
independent method such as environmen-
tal sampling. The ability ofa biomarker to
respond to specific conditions ofexposure
to a particular agent can be easily estab-
lished. To be ofvalue, a biomarker must be
sensitive enough to detect the exposures, or
their effects, that are actually experienced
by human populations.
The specificity ofa biomarker is a more
complex parameter to characterize and
apply to hazard evaluation. By analogy
with clinical laboratory tests, the specificity
ofa biomarker may be defined as the prob-
ability that it will not respond in a situa-
tion where a specific exposure does not
occur. In general, exposure biomarkers are
expected to be fairly specific. Since these
biomarkers detect the actual internal expo-
sure dose at a target tissue, they would not
be expected to detect an exposure when
none had occurred. On the other hand,
effect biomarkers detect biological responses
that occur after an exposure. In many cases
these responses may occur after exposure to
many different agents. For example, chro-
mosome damage in lymphocytes is a well-
documented response to many genotoxic
agents including radiation, drugs, and
environmental pollutants. Thus, as a bio-
marker, it has a rather low specificity. To
be useful in assessing the hazards associated
with a specific chemical or exposure sce-
nario, an effect biomarker would not be
useful unless the exposure experience ofthe
study population was well characterized.
The specificities of both exposure and
effect biomarkers may be influenced by a
variety of interfering factors. These might
include lifestyle activities of the members
of the study population, such as cigarette
smoking or ethanol consumption, expo-
sures to other agents in complex chemical
mixtures that might occur in an occupa-
tional setting, or exposure to ambient pol-
lutants in the environment. Lifestyle
activities of pregnant women may even
influence effect biomarkers in the fetus.
For example, the cord blood lymphocytes
ofnewborn infants ofmother who smoked
during pregnancy have elevated frequencies
ofHPRTmutant lymphocytes (12).
The consistency of response of a
biomarker may be an important factor in
its usefulness. Ifthe normal variance ofthe
biomarker response in a nonexposed popu-
lation is small relative to the mean, signifi-
cant increases in response will be easy to
detect using small numbers ofsamples. A
tight variance also suggests that the bio-
marker does not respond too strongly to
unrecognized factors in typical populations.
The statistical power of a biomarker
assay to detect reasonably sized changes in
response is an important characteristic that
must be known to design appropriate
studies. Sensitivity, specificity, and consis-
tency ofresponse are important parameters
in determining power. An assay that has a
low and consistent baseline value and is sen-
sitive enough to respond to an exposure with
a change in response of an easily observed
magnitude will be a useful biomarker. An
assay that requires a large sample popula-
tion or an unusually intense exposure will
not be useful in evaluating exposures.
Ifa biomarker is to be considered valid,
its ability to predict disease must be deter-
mined. Validation ofbiomarkers as predic-
tors ofhealth effects is a serious challenge.
However, the question of real interest is,
what is the relationship ofexposure to dis-
ease risk? The diseases that biomarkers are
intended to predict typically occur after
latencies of many years. Effect biomarkers
could be related to disease risk by carefully
determining the response ofthe biomarker
to exposure and then tracking the study
participants over time to associate bio-
marker responses with subsequent health
risk. This is a daunting task given the size
of the population that would have to be
evaluated and the time required to observe
subsequent disease. Despite the difficulties,
one such study has been conducted, the
Nordic Collaborative Study (13). In this
study chromosome aberration and sister
chromatid exchange (SCE) frequencies
were measured in workers in a variety of
industries in the Scandinavian countries.
The cohort has been followed for several
years and cases ofcancer identified. Using a
nested case-control design, records of the
earlier cytogenetic studies were compared
in the cancer cases and suitable controls
drawn from the cohort. A significant eleva-
tion in the odds ofhaving increased chro-
mosome damage but not SCEs was
observed in the cases (13).
Dr. Richard Albertini has suggested a
prospective study design that could effi-
ciently validate biomarkers in a period ofa
few years. Cancer patients who receive
alkylating agent therapy are at a signifi-
cantly elevated risk of developing leu-
kemias within 10 years or less following
treatment (14). Blood samples could be
obtained from patients before and soon
after treatment, and the lymphocytes and
other components could be cryopreserved
for later analysis. As the cohort ages,
patients who develop a second neoplasia
could be identified and matched with
patients who do not. Their cryopreserved
samples could then be tested and the
responses ofthe biomarkers determined for
the case and control groups (15). This
approach could be fairly efficient because
exposures would be precisely documented,
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and only a small percentage of the treated
patients would be likely to develop a sec-
ond neoplasia within 10 years. Effect bio-
markers such as the assay for mutation at
the HPRTgene could be evaluated. In
addition, biomarkers ofsusceptibility could
be characterized at the same time to deter-
mine their ability to predict risks from
exposure to alkylating agents.
Implementation Issues
Two practical issues that must be addressed
in order for the development ofbiomarkers
to progress are reduction ofcost and access
to populations for research. Currently, bio-
marker development and characterization
is a research activity. Typically, biomarker
assays are time consuming and expensive.
Analysis for DNA and protein adducts can
cost more than $100 per sample, while
tests requiring cell culture and subsequent
analysis can cost several hundred dollars
apiece. Since appropriate study designs
may require combined assessment of two
or more biomarkers, plus an exposure
assessment, the direct costs of a study ofa
population of 50 subjects could cost
$40,000 or more. At this price biomoni-
toring would not likely be attractive to
industry as a routine monitoring tool. As
biomarker techniques become more estab-
lished, a significant research need will be to
reduce their costs. This may be accom-
plished through modifications such as
automation ofassays or by reducing their
complexity and the need for advanced
technical skills to perform them.
The studies to develop, characterize,
and validate biomarkers cannot be con-
ducted unless populations are available to
investigators. Much early work has been
done with populations ofpatients exposed
to toxic drugs or with volunteers who
smoke cigarettes (10,12). Although such
populations have been helpful, access to
populations with well-documented expo-
sures to toxic chemicals in the workplace
are vitally needed to characterize biomarker
assays. Many studies have been carried out
in populations in developing nations or in
Eastern European Bloc nations where
occupational exposures to carcinogens are
currently relatively high (16,17). Although
studies of highly exposed populations in
developing countries are useful in method
development and mechanistic inquiries,
the only way to address the issues ofoccu-
pational health in typical United States
workplaces is to conduct studies in this
country. Studies in the United States
require cooperation of both labor unions
and employers. Without such cooperation,
studies are hampered by limited access to
facilities, restricted methods of exposure
assessment, and potential misclassification
of workers into inappropriate exposure
groups. Excellent examples ofsuch cooper-
ation can be noted. One is the landmark
study of the cytogenetic effects ofethylene
oxide exposure conducted with the cooper-
ation ofJohnson and Johnson (18). A sec-
ond is the participation ofTexaco Chemical
Company in studies of 1,3-butadiene
exposure (2,19,22).
There are legitimate ethical and legal
issues that inhibit employer participation
in the development of biomonitoring.
These issues, including how to explain
results to participants and the legal rami-
fications that may result for employers,
have been discussed from the beginning of
the use of biomarkers in human studies.
These issues are resolvable. As the value of
biomarkers and the need for them become
increasingly obvious, industry, labor,
and the research community need to com-
municate to develop guidelines for bio-
marker use and to plan studies to bring
biological monitoring into the modern
American workplace.
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